BCRX
BioCryst Pharmaceuticals, Inc. NASDAQ Listed Mar 4, 1994$9.14
+1.67%
vs $8.99
Mkt Cap $2.0B
52w Low $6.24
75.1% of range
52w High $10.10
50d MA $8.90
200d MA $7.94
P/E (TTM)
-5.1x
EV/EBITDA
—
P/B
—
Debt/Equity
-4.0x
ROE
-221.5%
P/FCF
6.1x
RSI (14)
63.60
ATR (14)
$0.34
Beta
0.69
50d MA
$8.90
200d MA
$7.94
Avg Volume
4.7M
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
4505 Emperor Boulevard · Durham, NC 27703 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | BMO | 0.07 | 1.12 | +1500.0% | 7.90 | +0.6% | +10.8% | -1.4% | +0.7% | -1.4% | -0.8% | — |
| Nov 3, 2025 | BMO | 0.07 | 0.06 | -14.3% | 6.86 | -2.3% | -1.5% | +6.1% | -2.0% | +0.9% | +1.6% | — |
| Aug 4, 2025 | BMO | 0.03 | 0.15 | +400.0% | 8.73 | -1.3% | -4.2% | +2.9% | -2.9% | -0.6% | -1.2% | — |
| May 5, 2025 | BMO | -0.07 | 0.00 | +100.3% | 11.03 | -0.5% | -6.9% | -1.9% | -1.6% | +0.5% | +3.7% | — |
| Feb 24, 2025 | BMO | -0.07 | -0.13 | -85.7% | 8.29 | +1.8% | -0.1% | +1.0% | +1.3% | +1.7% | -0.8% | — |
| Nov 4, 2024 | BMO | -0.07 | -0.07 | +0.0% | 7.35 | +0.4% | -3.9% | +9.5% | -0.8% | +1.4% | +5.3% | — |
| Aug 5, 2024 | BMO | -0.19 | -0.06 | +68.4% | 7.51 | +1.2% | +4.8% | -5.5% | +7.1% | -4.3% | +1.3% | — |
| May 6, 2024 | BMO | -0.23 | -0.17 | +26.1% | 5.27 | +2.3% | -0.2% | -3.0% | +4.7% | -0.4% | +5.8% | — |
| Feb 26, 2024 | BMO | -0.24 | -0.28 | -16.7% | 5.79 | +1.7% | +1.4% | -2.7% | -1.4% | -0.2% | -2.0% | — |
| Nov 2, 2023 | BMO | -0.25 | -0.19 | +24.0% | 5.64 | +3.0% | +7.1% | -1.8% | +2.4% | -9.9% | -8.4% | — |
| Aug 3, 2023 | BMO | -0.25 | -0.24 | +4.0% | 7.08 | +4.1% | +7.3% | -11.7% | +4.6% | -0.4% | +1.1% | — |
| May 3, 2023 | BMO | -0.30 | -0.28 | +6.7% | 8.29 | +0.7% | +2.2% | +1.1% | -0.8% | +1.1% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30 | RBC Capital | Maintains | Outperform → Outperform | — | $6.67 | $6.61 | -0.9% | -1.3% | +0.8% | +1.1% | -4.2% | -2.8% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.57 | $7.64 | +0.9% | +0.3% | -1.6% | -4.6% | +2.2% | +1.6% |
| Nov 5 | Citizens | Maintains | Market Outperform → Market Outperform | — | $6.76 | $6.86 | +1.5% | +6.1% | -2.0% | +0.9% | +1.6% | +0.4% |
| Nov 4 | Barclays | Maintains | Equal Weight → Equal Weight | — | $6.86 | $6.70 | -2.3% | -1.5% | +6.1% | -2.0% | +0.9% | +1.6% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $6.86 | $6.70 | -2.3% | -1.5% | +6.1% | -2.0% | +0.9% | +1.6% |
| Oct 15 | Needham | Maintains | Buy → Buy | — | $6.42 | $6.53 | +1.7% | +6.1% | -1.3% | -1.3% | +4.5% | +0.9% |
| Oct 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.42 | $6.53 | +1.7% | +6.1% | -1.3% | -1.3% | +4.5% | +0.9% |
| Oct 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.42 | $6.53 | +1.7% | +6.1% | -1.3% | -1.3% | +4.5% | +0.9% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $7.95 | $9.14 | +15.0% | +9.8% | -4.2% | +2.9% | -2.9% | -0.6% |
| Jul 1 | BofA Securities | Maintains | Buy → Buy | — | $8.96 | $8.98 | +0.2% | +0.4% | +0.2% | -0.9% | -2.0% | +0.3% |
| Jun 30 | Wedbush | Maintains | Outperform → Outperform | — | $9.36 | $9.47 | +1.2% | -4.3% | +0.4% | +0.2% | -0.9% | -2.0% |
| Jun 30 | RBC Capital | Maintains | Outperform → Outperform | — | $9.36 | $9.47 | +1.2% | -4.3% | +0.4% | +0.2% | -0.9% | -2.0% |
| Jun 27 | Needham | Maintains | Buy → Buy | — | $9.66 | $10.05 | +4.0% | -3.1% | -4.3% | +0.4% | +0.2% | -0.9% |
| Jun 25 | Needham | Maintains | Buy → Buy | — | $9.93 | $9.94 | +0.1% | -1.9% | -0.8% | -3.1% | -4.3% | +0.4% |
| May 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $10.27 | $10.36 | +0.9% | -1.9% | -1.6% | +0.5% | +3.7% | -2.7% |
| May 6 | Needham | Maintains | Buy → Buy | — | $11.03 | $10.97 | -0.5% | -6.9% | -1.9% | -1.6% | +0.5% | +3.7% |
| May 6 | JP Morgan | Maintains | Overweight → Overweight | — | $11.03 | $10.97 | -0.5% | -6.9% | -1.9% | -1.6% | +0.5% | +3.7% |
| May 6 | RBC Capital | Maintains | Outperform → Outperform | — | $11.03 | $10.97 | -0.5% | -6.9% | -1.9% | -1.6% | +0.5% | +3.7% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.03 | $10.97 | -0.5% | -6.9% | -1.9% | -1.6% | +0.5% | +3.7% |
| Apr 11 | RBC Capital | Maintains | Outperform → Outperform | — | $6.41 | $6.33 | -1.2% | +6.4% | +3.2% | +5.1% | -2.4% | +2.5% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $6.77 | $6.57 | -3.0% | -5.3% | +6.4% | +3.2% | +5.1% | -2.4% |
| Mar 3 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $8.61 | $8.58 | -0.3% | -0.8% | -2.7% | -3.1% | -2.4% | -2.2% |
| Feb 25 | RBC Capital | Maintains | Outperform → Outperform | — | $8.29 | $8.44 | +1.8% | -0.1% | +1.0% | +1.3% | +1.7% | -0.8% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.29 | $8.44 | +1.8% | -0.1% | +1.0% | +1.3% | +1.7% | -0.8% |
| Feb 25 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $8.29 | $8.44 | +1.8% | -0.1% | +1.0% | +1.3% | +1.7% | -0.8% |
| Jan 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.87 | $7.86 | -0.1% | +0.4% | -3.5% | +6.2% | +6.4% | +1.4% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $7.67 | $7.77 | +1.3% | +3.4% | -8.8% | +0.0% | -2.4% | +5.5% |
| Jan 13 | Evercore ISI | Maintains | Outperform → Outperform | — | $7.67 | $7.77 | +1.3% | +3.4% | -8.8% | +0.0% | -2.4% | +5.5% |
| Dec 17 | Needham | Maintains | Buy → Buy | — | $7.46 | $7.23 | -3.1% | +0.4% | -2.4% | +1.1% | +2.4% | +2.8% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $7.35 | $7.38 | +0.4% | -3.9% | +9.5% | -0.8% | +1.4% | +5.3% |
| Nov 5 | Barclays | Maintains | Equal Weight → Equal Weight | — | $7.35 | $7.38 | +0.4% | -3.9% | +9.5% | -0.8% | +1.4% | +5.3% |
| Nov 5 | RBC Capital | Maintains | Outperform → Outperform | — | $7.35 | $7.38 | +0.4% | -3.9% | +9.5% | -0.8% | +1.4% | +5.3% |
| Aug 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $7.51 | $7.60 | +1.2% | +4.8% | -5.5% | +7.1% | -4.3% | +1.3% |
| Aug 6 | RBC Capital | Maintains | Outperform → Outperform | — | $7.51 | $7.60 | +1.2% | +4.8% | -5.5% | +7.1% | -4.3% | +1.3% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.51 | $7.60 | +1.2% | +4.8% | -5.5% | +7.1% | -4.3% | +1.3% |
| Aug 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.51 | $7.60 | +1.2% | +4.8% | -5.5% | +7.1% | -4.3% | +1.3% |
| May 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.27 | $5.39 | +2.3% | -0.2% | -3.0% | +4.7% | -0.4% | +5.8% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.27 | $5.39 | +2.3% | -0.2% | -3.0% | +4.7% | -0.4% | +5.8% |
| May 7 | Needham | Maintains | Buy → Buy | — | $5.27 | $5.39 | +2.3% | -0.2% | -3.0% | +4.7% | -0.4% | +5.8% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $4.80 | $4.64 | -3.3% | +1.5% | +4.7% | -6.5% | -2.1% | -1.3% |
| Jan 8 | Needham | Maintains | Buy → Buy | — | $6.09 | $6.30 | +3.4% | +25.6% | -2.7% | -7.5% | -6.0% | -1.9% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $6.04 | $6.19 | +2.5% | -1.8% | +2.4% | -9.9% | -8.4% | -0.6% |
| Sep 25 | RBC Capital | Maintains | Outperform → Outperform | — | $7.35 | $7.30 | -0.7% | +0.3% | -0.3% | +2.3% | -3.7% | -2.2% |
| Sep 18 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $6.85 | $7.20 | +5.1% | +9.9% | +1.6% | -7.1% | +0.7% | +2.7% |
| Aug 4 | Jefferies | Upgrade | Hold → Buy | — | $7.08 | $7.37 | +4.1% | +7.3% | -11.7% | +4.6% | -0.4% | +1.1% |
| Aug 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $7.08 | $7.37 | +4.1% | +7.3% | -11.7% | +4.6% | -0.4% | +1.1% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.08 | $7.37 | +4.1% | +7.3% | -11.7% | +4.6% | -0.4% | +1.1% |
| Jul 13 | BofA Securities | Upgrade | Neutral → Buy | — | $7.18 | $7.65 | +6.5% | +2.4% | -3.0% | +0.8% | -0.3% | +2.6% |
| May 4 | Needham | Maintains | Buy → Buy | — | $8.29 | $8.35 | +0.7% | +2.2% | +1.1% | -0.8% | +1.1% | +0.6% |
| May 4 | RBC Capital | Maintains | Sector Perform → Perform | — | $8.29 | $8.35 | +0.7% | +2.2% | +1.1% | -0.8% | +1.1% | +0.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | McKee Amy EDir | — | Sell | 11,180 | $8.97 | $100K | 31,252 | -0.34% | +7.67% |
| May 13, 2026 | Barnes Alane POff | Chief Legal Officer | Sell | 62,500 | $9.54 | $596K | 400,703 | -0.55% | -0.96% |
8-K · 2.02
!! High
Tenax Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 2.02
!! High
BioCryst Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
BioCryst Pharmaceuticals reported quarterly earnings results, with detailed financial performance and operational updates available in the accompanying press release exhibit.
May 6
8-K · 7.01
! Medium
BioCryst Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
BioCryst Pharmaceuticals secured $70 million upfront plus up to $275 million in milestones by granting exclusive European commercialization rights for navenibart to treat hereditary angioedema.
May 4
8-K
Tenax Therapeutics, Inc. -- 8-K Filing
Tenax Therapeutics' CFO previously led Triangle Pharmaceuticals through its acquisition by Gilead Sciences, demonstrating experience navigating pharma M&A transactions that could benefit Tenax shareholders.
Apr 22
8-K · 7.01
! Medium
BioCryst Pharmaceuticals Inc -- 8-K 7.01: Regulation FD Disclosure
BioCryst Pharmaceuticals disclosed material information via Exhibit 99.1, requiring investors to review the attached document for potentially significant developments affecting the company's financial position or operations.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Deerfield Management Company, L.p. | 15,038,000 | $143M | Added | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 11,244,625 | $107M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 11,135,762 | $106M | New | Mar 2026 |
| 4 | Janus Henderson Group Plc | 8,908,506 | $85M | New | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 6,392,628 | $61M | Added | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 5,091,765 | $48M | Added | Mar 2026 |
| 7 | Aberdeen Group Plc | 5,040,670 | $48M | Added | Mar 2026 |
| 8 | Ubs Group Ag | 4,943,994 | $47M | Reduced | Mar 2026 |
| 9 | Royalty Pharma Sub-Manager, Llc | 3,846,154 | $37M | — | Mar 2026 |
| 10 | Nuveen, Llc | 3,819,263 | $36M | Added | Mar 2026 |
| 11 | Rfg Advisory, Llc | 2,870,700 | $27M | New | Mar 2026 |
| 12 | Morgan Stanley | 3,491,126 | $27M | Reduced | Dec 2025 |
| 13 | Susquehanna International Group, Llp | 2,815,304 | $27M | Added | Mar 2026 |
| 14 | Op Asset Management Ltd | 2,505,726 | $26M | Added | Mar 2026 |
| 15 | Northern Trust Corp | 2,104,725 | $20M | Added | Mar 2026 |
| 16 | Rice Hall James & Associates, Llc | 1,904,146 | $15M | Added | Dec 2025 |
| 17 | Jpmorgan Chase & Co | 1,541,978 | $15M | Added | Mar 2026 |
| 18 | Invesco Ltd. | 1,308,813 | $12M | Reduced | Mar 2026 |
| 19 | Bnp Paribas Financial Markets | 1,302,257 | $12M | Reduced | Mar 2026 |
| 20 | Man Group Plc | 1,293,300 | $12M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.00B
Enterprise Value
$2.15B
P/E (TTM)
-5.13x
Forward P/E
33.78x
PEG Ratio
-0.02x
P/B
—
P/S
2.26x
P/FCF
6.10x
EV/EBITDA
—
Shares Out
218.6M
Financials (TTM)
Revenue
$885.7M
Net Income
-$458.0M
EBITDA
-$373.2M
Free Cash Flow
$327.4M
Op Cash Flow
$329.9M
EPS Basic
$1.26
EPS Diluted
$-1.78
EPS Forward
$0.27
Gross Margin
18.9%
Op Margin
-43.1%
Net Margin
-51.7%
Balance Sheet
Total Assets
$514.2M
Total Liab.
$633.3M
Total Equity
-$119.2M
Cash
$274.7M
LT Debt
$427.2M
Book Value/Sh
$-0.57
Debt/Equity
-4.01x
Current Ratio
2.06
Quick Ratio
2.03
Returns & Growth
ROE
-221.5%
ROA
51.3%
ROIC
93.9%
Rev Growth YoY
+94.1%
EPS Growth YoY
+393.0%
Price Returns
2W
-6.9%
1M
-2.7%
3M
+1.8%
6M
+24.1%
12M
-17.1%
Technicals
52W High
$10.10
52W Low
$6.24
50d MA
$8.90
200d MA
$7.94
RSI (14)
63.60
ATR (14)
$0.34
Beta
0.69
Avg Volume
4.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$17.00
High
$25.00
Low
$9.00
Median
$17.00
Data updated apr 24, 2026 8:57pm
· Source: financialmodelingprep.com